Olaparib

The FDA granted priority review to olaparib in combination with bevacizumab as first-line maintenance treatment of women with advanced ovarian cancer, according to the agent’s manufacturer.

The FDA approved olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer, according to a press release from the drug’s manufacturer.

An FDA panel today supported approval of olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer.

In this supplement to HemOnc Today, we have compiled the most-read articles written about ovarian cancer this year. From risk reducing measures (below) to improving progression-free survival (pages 12 and 14), our experts researched and weighed in on the spectrum of this deadly carcinoma. “These are exciting times in ovarian cancer research and, more importantly, for patients. Recent discoveries have realized the possibility that this is the beginning of the end of ovarian cancer,” Michael J. Birrer, MD, PhD, writes in his editorial (page 10). “Our new understanding of the origins of this disease may give rise to a reasonably effective early detection assay, which remains the holy grail of ovarian cancer research.” To follow along this journey, be sure to follow @HemOncToday on Twitter and visit Healio.com regularly.

BARCELONA, Spain — Olaparib significantly improved radiographic PFS compared with horomone therapy for men with metastatic castration-resistant prostate cancer who had homologous recombination repair gene alterations and received prior treatment with new hormonal agents, according to results of the randomized phase 3 PROfound study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The addition of olaparib to bevacizumab maintenance therapy after first-line platinum-based chemotherapy and bevacizumab significantly improved PFS among women with advanced ovarian cancer, according to results of the randomized phase 3 PAOLA-1/ENGOT-ov25 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The combination of cediranib and olaparib appeared to be effective and safe for women with heavily pretreated, platinum-resistant ovarian cancer, according to results of a randomized phase 2 study presented at European Society for Medical Oncology Congress.

The introduction of poly (ADP-ribose) polymerase, or PARP, inhibitors has made a significant impact in ovarian cancer, prolonging PFS among certain patients, particularly those with BRCA mutations.